5,000 Patients Treated Globally The versatility and innovation of Abiomed's (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption
5,000 Patients Treated GloballyDANVERS, Mass. (BUSINESS WIRE) The versatility and innovation of Abiomed’s (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. Today, Abiomed announce.